1 Green Flag for Eli Lilly Investors in 2022 -- and 1 Red Flag

Pharma giant Eli Lilly & Company (NYSE: LLY) has performed splendidly in the past year, leaving both the broader market and the pharmaceutical industry in the dust. But it's difficult to predict whether the company will continue on its upward trajectory for the rest of the year. Geopolitical tensions, which are already high, could escalate further and send Eli Lilly (along with the rest of the market) crashing.

If we put these marketwide worries aside, though, there is at least one key reason why the future looks bright for Eli Lilly. On the other hand, there is also a company-specific reason why investors might want to stay away from the stock for now.

Source Fool.com